{"id":"placebo-to-oseltamivir","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"5","effect":"Diarrhea"},{"rate":"2","effect":"Headache"},{"rate":"2","effect":"Bronchitis"}]},"_chembl":{"chemblId":"CHEMBL1229","moleculeType":"Small molecule","molecularWeight":"312.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir is a neuraminidase inhibitor that blocks the viral neuraminidase enzyme, preventing influenza virus particles from being released from infected cells and reducing viral spread. The trial is evaluating oseltamivir's efficacy and safety compared to placebo in treating or preventing influenza infection. This is a comparative effectiveness study rather than a novel drug development program.","oneSentence":"This is a Phase 3 clinical trial comparing placebo to oseltamivir (Tamiflu), an antiviral neuraminidase inhibitor used to treat influenza.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection"},{"name":"Prophylaxis of influenza in exposed individuals"}]},"trialDetails":[{"nctId":"NCT07236814","phase":"PHASE3","title":"Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-11-28","conditions":"Influenza","enrollment":384},{"nctId":"NCT07357051","phase":"PHASE3","title":"Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","status":"RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-11-07","conditions":"Respiratory Viral Infection","enrollment":177},{"nctId":"NCT07095257","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza","status":"RECRUITING","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2025-10-13","conditions":"Respiratory Viral Infection","enrollment":168},{"nctId":"NCT06507813","phase":"PHASE3","title":"Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza","status":"COMPLETED","sponsor":"Jiaxing AnDiCon Biotech Co.,Ltd","startDate":"2024-08-19","conditions":"Influenza Type A, Influenza Type B","enrollment":190},{"nctId":"NCT06669351","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza","status":"TERMINATED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2024-10-31","conditions":"Respiratory Viral Infection","enrollment":98},{"nctId":"NCT05818124","phase":"PHASE1","title":"Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-21","conditions":"Influenza Infection","enrollment":161},{"nctId":"NCT05170009","phase":"PHASE2, PHASE3","title":"Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2022-04-22","conditions":"Influenza","enrollment":2},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":"Severe Viral Pneumonia(Not Include COVID-19)","enrollment":60},{"nctId":"NCT03900988","phase":"PHASE3","title":"Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-08","conditions":"Influenza","enrollment":160},{"nctId":"NCT04683406","phase":"PHASE3","title":"A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2020-12-28","conditions":"Influenza A","enrollment":750},{"nctId":"NCT04982913","phase":"PHASE1","title":"Single Dose and Multiple Dose Safety, Tolerability, PK，and Food Effect Study，and Interaction With Oseltamivir Study of HEC116094 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-08-24","conditions":"Influenza","enrollment":118},{"nctId":"NCT03212716","phase":"PHASE2","title":"Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2017-12-23","conditions":"Flu","enrollment":85},{"nctId":"NCT03040141","phase":"PHASE2","title":"Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A","status":"COMPLETED","sponsor":"Visterra, Inc.","startDate":"2018-01-03","conditions":"Influenza A","enrollment":89},{"nctId":"NCT04523090","phase":"PHASE2, PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":"COVID-19","enrollment":322},{"nctId":"NCT03684044","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-08","conditions":"Influenza","enrollment":363},{"nctId":"NCT02927431","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-01-19","conditions":"Virus Diseases","enrollment":10},{"nctId":"NCT03629184","phase":"PHASE3","title":"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-20","conditions":"Influenza","enrollment":173},{"nctId":"NCT02532283","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-12-11","conditions":"Influenza A Virus","enrollment":102},{"nctId":"NCT03903718","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2020-04-03","conditions":"Influenza","enrollment":""},{"nctId":"NCT02949011","phase":"PHASE3","title":"Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications","status":"COMPLETED","sponsor":"Shionogi","startDate":"2017-01-11","conditions":"Influenza","enrollment":2184},{"nctId":"NCT03238612","phase":"PHASE2","title":"Flufenamic Acid for Hospitalised Influenza Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2018-01-08","conditions":"Influenza A","enrollment":200},{"nctId":"NCT02108366","phase":"PHASE3","title":"Treatment of Severe Influenza A Infection","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-03","conditions":"Influenza, Human","enrollment":107},{"nctId":"NCT02469298","phase":"PHASE2","title":"Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-01","conditions":"Virus Diseases","enrollment":45},{"nctId":"NCT02954354","phase":"PHASE3","title":"A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza","status":"COMPLETED","sponsor":"Shionogi","startDate":"2016-12-08","conditions":"Influenza","enrollment":1436},{"nctId":"NCT03028909","phase":"PHASE2","title":"Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2017-07-24","conditions":"Influenza - Type A Strains","enrollment":""},{"nctId":"NCT00803595","phase":"PHASE3","title":"A Multinational Phase III Study of CS-8958 (MARVEL)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-11","conditions":"Influenza, Human","enrollment":1002},{"nctId":"NCT02282384","phase":"PHASE4","title":"An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.","status":"WITHDRAWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Pulmonary Disease, Influenza","enrollment":""},{"nctId":"NCT00555893","phase":"NA","title":"Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2008-01","conditions":"Influenza","enrollment":194},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626},{"nctId":"NCT00545532","phase":"PHASE3","title":"A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-02-04","conditions":"Influenza, Human","enrollment":228},{"nctId":"NCT02293863","phase":"PHASE2","title":"A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-01-14","conditions":"Influenza","enrollment":168},{"nctId":"NCT02603952","phase":"PHASE1, PHASE2","title":"A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2015-12-07","conditions":"Influenza","enrollment":126},{"nctId":"NCT01610245","phase":"PHASE3","title":"Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2013-03","conditions":"Influenza","enrollment":1941},{"nctId":"NCT02561169","phase":"PHASE4","title":"A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza","status":"TERMINATED","sponsor":"McMaster University","startDate":"2015-12","conditions":"Influenza","enrollment":1},{"nctId":"NCT01980966","phase":"PHASE2","title":"A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-11-25","conditions":"Healthy Volunteer","enrollment":101},{"nctId":"NCT02717754","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Healthy Volunteer","enrollment":99},{"nctId":"NCT00412737","phase":"PHASE4","title":"A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-01","conditions":"Influenza","enrollment":477},{"nctId":"NCT02262715","phase":"PHASE1","title":"A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir","status":"COMPLETED","sponsor":"Janssen Infectious Diseases BVBA","startDate":"2014-07","conditions":"Healthy","enrollment":38},{"nctId":"NCT01690637","phase":"PHASE4","title":"Panama and El Salvador Children's Oseltamivir Study","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-09","conditions":"Influenza, Human Influenza","enrollment":721},{"nctId":"NCT01708369","phase":"PHASE1","title":"Alcohol Inhibits Drug Metabolism by Carboxylesterases","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2012-02","conditions":"Drug Interactions","enrollment":19},{"nctId":"NCT01032837","phase":"PHASE4","title":"A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Influenza","enrollment":102},{"nctId":"NCT00980109","phase":"PHASE4","title":"Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-09","conditions":"Influenza","enrollment":390},{"nctId":"NCT00593502","phase":"PHASE4","title":"Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age","status":"COMPLETED","sponsor":"Hospital District of Southwestern Finland","startDate":"2008-02","conditions":"Influenza","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":180,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Oseltamivir","genericName":"Placebo to Oseltamivir","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a Phase 3 clinical trial comparing placebo to oseltamivir (Tamiflu), an antiviral neuraminidase inhibitor used to treat influenza. Used for Treatment of acute uncomplicated influenza A and B infection, Prophylaxis of influenza in exposed individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}